Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

IDO1 inhibition for Alzheimer’s disease

Elizabeth Stivison
October 2, 2024 5:47 PM UTC

Inhibiting the kynurenine synthesis enzyme IDO1, which is activated by Aβ and tau, could help treat Alzheimer’s disease by decreasing kynurenine production and its downstream signaling in astrocytes, thus normalizing glucose metabolism in the hippocampus and increasing astrocytes’ ability to export lactate and support neuronal metabolism.

In postmortem brain tissue of Alzheimer’s patients, kynurenine was increased compared with non-Alzheimer's controls. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Stanford University